SGLT2 Inhibitors Market Size, Trends, Analysis, and Outlook By Drug (Sodium Glucose C-transport -2 (SGLT-2) Inhibitor, Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), Suglat (Ipragliflozin)), by Country, Segment, and Companies, 2024-2032
The global SGLT2 Inhibitors market size is poised to register 8.9% growth from 2024 to 2032, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global SGLT2 Inhibitors market across By Drug (Sodium Glucose C-transport -2 (SGLT-2) Inhibitor, Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), Suglat (Ipragliflozin))
The sodium-glucose cotransporter-2 (SGLT2) inhibitors market is driven by the increasing prevalence of type 2 diabetes, obesity-related metabolic disorders, and cardiovascular complications, alongside advancements in pharmacotherapy offering renal and cardiovascular benefits beyond glycemic control. With a growing emphasis on multifactorial risk reduction and disease management, there's a demand for SGLT2 inhibitors offering improved cardiovascular outcomes, kidney protection, and weight loss in individuals with diabetes and related comorbidities. By 2030, the market is expected to witness expanded indications, combination therapies, and precision medicine approaches leveraging biomarkers and digital health technologies, optimizing treatment strategies and improving long-term clinical outcomes for patients with type 2 diabetes and cardiometabolic conditions.
SGLT2 Inhibitors Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The SGLT2 Inhibitors market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of SGLT2 Inhibitors survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the SGLT2 Inhibitors industry.
Key market trends defining the global SGLT2 Inhibitors demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
SGLT2 Inhibitors Market Segmentation- Industry Share, Market Size, and Outlook to 2032
The SGLT2 Inhibitors industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support SGLT2 Inhibitors companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the SGLT2 Inhibitors industry
Leading SGLT2 Inhibitors companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 SGLT2 Inhibitors companies.
SGLT2 Inhibitors Market Study- Strategic Analysis Review
The SGLT2 Inhibitors market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
The SGLT2 Inhibitors industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2032 in three case scenarios- low case, reference case, and high case scenarios.
SGLT2 Inhibitors Country Analysis and Revenue Outlook to 2032
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2032. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2032.
North America SGLT2 Inhibitors Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong healthcare infrastructure. Leading companies focus on new product launches in the changing environment. The US healthcare expenditure is expected to grow to $4.8 trillion in 2024 (around 3.7% growth in 2024), potentially driving demand for various SGLT2 Inhibitors market segments. Similarly, Strong market demand is encouraging Canadian SGLT2 Inhibitors companies to invest in niche segments. Further, as Mexico continues to strengthen its relations and invest in technological advancements, the Mexico SGLT2 Inhibitors market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe SGLT2 Inhibitors Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European SGLT2 Inhibitors industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of vendors in identifying and leveraging new growth prospects positions the European SGLT2 Inhibitors market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific SGLT2 Inhibitors Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for SGLT2 Inhibitors in Asia Pacific. In particular, China, India, and South East Asian SGLT2 Inhibitors markets present a compelling outlook for 2032, acting as a magnet for both domestic and multinational vendors seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major countries in the APAC region.
Latin America SGLT2 Inhibitors Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa SGLT2 Inhibitors Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East SGLT2 Inhibitors market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for SGLT2 Inhibitors.
SGLT2 Inhibitors Market Company Profiles
The global SGLT2 Inhibitors market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Astellas Pharma Inc, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceuticals Inc.
Recent SGLT2 Inhibitors Market Developments
The global SGLT2 Inhibitors market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
SGLT2 Inhibitors Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2032 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
By Drug
Sodium - Glucose C-transport -2 (SGLT-2) Inhibitor
-Invokana (Canagliflozin)
-Jardiance (Empagliflozin)
-Farxiga/Forxiga (Dapagliflozin)
-Suglat (Ipragliflozin)
Geographical Segmentation:
Astellas Pharma Inc
AstraZeneca PLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
Janssen Pharmaceuticals Inc
Formats Available: Excel, PDF, and PPT
The sodium-glucose cotransporter-2 (SGLT2) inhibitors market is driven by the increasing prevalence of type 2 diabetes, obesity-related metabolic disorders, and cardiovascular complications, alongside advancements in pharmacotherapy offering renal and cardiovascular benefits beyond glycemic control. With a growing emphasis on multifactorial risk reduction and disease management, there's a demand for SGLT2 inhibitors offering improved cardiovascular outcomes, kidney protection, and weight loss in individuals with diabetes and related comorbidities. By 2030, the market is expected to witness expanded indications, combination therapies, and precision medicine approaches leveraging biomarkers and digital health technologies, optimizing treatment strategies and improving long-term clinical outcomes for patients with type 2 diabetes and cardiometabolic conditions.
SGLT2 Inhibitors Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The SGLT2 Inhibitors market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of SGLT2 Inhibitors survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the SGLT2 Inhibitors industry.
Key market trends defining the global SGLT2 Inhibitors demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
SGLT2 Inhibitors Market Segmentation- Industry Share, Market Size, and Outlook to 2032
The SGLT2 Inhibitors industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support SGLT2 Inhibitors companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the SGLT2 Inhibitors industry
Leading SGLT2 Inhibitors companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 SGLT2 Inhibitors companies.
SGLT2 Inhibitors Market Study- Strategic Analysis Review
The SGLT2 Inhibitors market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
- Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
- Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
- Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
- Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.
The SGLT2 Inhibitors industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2032 in three case scenarios- low case, reference case, and high case scenarios.
SGLT2 Inhibitors Country Analysis and Revenue Outlook to 2032
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2032. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2032.
North America SGLT2 Inhibitors Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong healthcare infrastructure. Leading companies focus on new product launches in the changing environment. The US healthcare expenditure is expected to grow to $4.8 trillion in 2024 (around 3.7% growth in 2024), potentially driving demand for various SGLT2 Inhibitors market segments. Similarly, Strong market demand is encouraging Canadian SGLT2 Inhibitors companies to invest in niche segments. Further, as Mexico continues to strengthen its relations and invest in technological advancements, the Mexico SGLT2 Inhibitors market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe SGLT2 Inhibitors Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European SGLT2 Inhibitors industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of vendors in identifying and leveraging new growth prospects positions the European SGLT2 Inhibitors market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific SGLT2 Inhibitors Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for SGLT2 Inhibitors in Asia Pacific. In particular, China, India, and South East Asian SGLT2 Inhibitors markets present a compelling outlook for 2032, acting as a magnet for both domestic and multinational vendors seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major countries in the APAC region.
Latin America SGLT2 Inhibitors Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa SGLT2 Inhibitors Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East SGLT2 Inhibitors market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for SGLT2 Inhibitors.
SGLT2 Inhibitors Market Company Profiles
The global SGLT2 Inhibitors market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Astellas Pharma Inc, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceuticals Inc.
Recent SGLT2 Inhibitors Market Developments
The global SGLT2 Inhibitors market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
SGLT2 Inhibitors Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2032 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
- Pricing Analysis
- Value Chain Analysis
- SWOT Profile
- Market Dynamics- Trends, Drivers, Challenges
- Porter’s Five Forces Analysis
- Macroeconomic Impact Analysis
- Case Scenarios- Low, Base, High
By Drug
Sodium - Glucose C-transport -2 (SGLT-2) Inhibitor
-Invokana (Canagliflozin)
-Jardiance (Empagliflozin)
-Farxiga/Forxiga (Dapagliflozin)
-Suglat (Ipragliflozin)
Geographical Segmentation:
- North America (3 markets)
- Europe (6 markets)
- Asia Pacific (6 markets)
- Latin America (3 markets)
- Middle East Africa (5 markets)
Astellas Pharma Inc
AstraZeneca PLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
Janssen Pharmaceuticals Inc
Formats Available: Excel, PDF, and PPT
1. EXECUTIVE SUMMARY
1.1 SGLT2 Inhibitors Market Overview and Key Findings, 2024
1.2 SGLT2 Inhibitors Market Size and Growth Outlook, 2021- 2030
1.3 SGLT2 Inhibitors Market Growth Opportunities to 2030
1.4 Key SGLT2 Inhibitors Market Trends and Challenges
1.4.1 SGLT2 Inhibitors Market Drivers and Trends
1.4.2 SGLT2 Inhibitors Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading SGLT2 Inhibitors Companies
2. SGLT2 INHIBITORS MARKET SIZE OUTLOOK TO 2030
2.1 SGLT2 Inhibitors Market Size Outlook, USD Million, 2021- 2030
2.2 SGLT2 Inhibitors Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. SGLT2 INHIBITORS MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. SGLT2 INHIBITORS MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Drug
Sodium - Glucose C-transport -2 (SGLT-2) Inhibitor
-Invokana (Canagliflozin)
-Jardiance (Empagliflozin)
-Farxiga/Forxiga (Dapagliflozin)
-Suglat (Ipragliflozin)
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific SGLT2 Inhibitors Market, 2025
5.2 Asia Pacific SGLT2 Inhibitors Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific SGLT2 Inhibitors Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe SGLT2 Inhibitors Market, 2025
5.5 Europe SGLT2 Inhibitors Market Size Outlook by Type, 2021- 2030
5.6 Europe SGLT2 Inhibitors Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America SGLT2 Inhibitors Market, 2025
5.8 North America SGLT2 Inhibitors Market Size Outlook by Type, 2021- 2030
5.9 North America SGLT2 Inhibitors Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America SGLT2 Inhibitors Market, 2025
5.11 South America Pacific SGLT2 Inhibitors Market Size Outlook by Type, 2021- 2030
5.12 South America SGLT2 Inhibitors Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa SGLT2 Inhibitors Market, 2025
5.14 Middle East Africa SGLT2 Inhibitors Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa SGLT2 Inhibitors Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US SGLT2 Inhibitors Market Size Outlook and Revenue Growth Forecasts
6.2 US SGLT2 Inhibitors Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada SGLT2 Inhibitors Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico SGLT2 Inhibitors Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany SGLT2 Inhibitors Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France SGLT2 Inhibitors Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK SGLT2 Inhibitors Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain SGLT2 Inhibitors Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy SGLT2 Inhibitors Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe SGLT2 Inhibitors Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China SGLT2 Inhibitors Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India SGLT2 Inhibitors Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan SGLT2 Inhibitors Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea SGLT2 Inhibitors Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia SGLT2 Inhibitors Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia SGLT2 Inhibitors Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific SGLT2 Inhibitors Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil SGLT2 Inhibitors Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina SGLT2 Inhibitors Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America SGLT2 Inhibitors Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East SGLT2 Inhibitors Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa SGLT2 Inhibitors Industry Drivers and Opportunities
7. SGLT2 INHIBITORS MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. SGLT2 INHIBITORS COMPANY PROFILES
8.1 Profiles of Leading SGLT2 Inhibitors Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
Astellas Pharma Inc
AstraZeneca PLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
Janssen Pharmaceuticals Inc.
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
1.1 SGLT2 Inhibitors Market Overview and Key Findings, 2024
1.2 SGLT2 Inhibitors Market Size and Growth Outlook, 2021- 2030
1.3 SGLT2 Inhibitors Market Growth Opportunities to 2030
1.4 Key SGLT2 Inhibitors Market Trends and Challenges
1.4.1 SGLT2 Inhibitors Market Drivers and Trends
1.4.2 SGLT2 Inhibitors Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading SGLT2 Inhibitors Companies
2. SGLT2 INHIBITORS MARKET SIZE OUTLOOK TO 2030
2.1 SGLT2 Inhibitors Market Size Outlook, USD Million, 2021- 2030
2.2 SGLT2 Inhibitors Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. SGLT2 INHIBITORS MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. SGLT2 INHIBITORS MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Drug
Sodium - Glucose C-transport -2 (SGLT-2) Inhibitor
-Invokana (Canagliflozin)
-Jardiance (Empagliflozin)
-Farxiga/Forxiga (Dapagliflozin)
-Suglat (Ipragliflozin)
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific SGLT2 Inhibitors Market, 2025
5.2 Asia Pacific SGLT2 Inhibitors Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific SGLT2 Inhibitors Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe SGLT2 Inhibitors Market, 2025
5.5 Europe SGLT2 Inhibitors Market Size Outlook by Type, 2021- 2030
5.6 Europe SGLT2 Inhibitors Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America SGLT2 Inhibitors Market, 2025
5.8 North America SGLT2 Inhibitors Market Size Outlook by Type, 2021- 2030
5.9 North America SGLT2 Inhibitors Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America SGLT2 Inhibitors Market, 2025
5.11 South America Pacific SGLT2 Inhibitors Market Size Outlook by Type, 2021- 2030
5.12 South America SGLT2 Inhibitors Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa SGLT2 Inhibitors Market, 2025
5.14 Middle East Africa SGLT2 Inhibitors Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa SGLT2 Inhibitors Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US SGLT2 Inhibitors Market Size Outlook and Revenue Growth Forecasts
6.2 US SGLT2 Inhibitors Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada SGLT2 Inhibitors Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico SGLT2 Inhibitors Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany SGLT2 Inhibitors Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France SGLT2 Inhibitors Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK SGLT2 Inhibitors Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain SGLT2 Inhibitors Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy SGLT2 Inhibitors Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe SGLT2 Inhibitors Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China SGLT2 Inhibitors Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India SGLT2 Inhibitors Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan SGLT2 Inhibitors Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea SGLT2 Inhibitors Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia SGLT2 Inhibitors Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia SGLT2 Inhibitors Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific SGLT2 Inhibitors Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil SGLT2 Inhibitors Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina SGLT2 Inhibitors Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America SGLT2 Inhibitors Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East SGLT2 Inhibitors Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa SGLT2 Inhibitors Industry Drivers and Opportunities
7. SGLT2 INHIBITORS MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. SGLT2 INHIBITORS COMPANY PROFILES
8.1 Profiles of Leading SGLT2 Inhibitors Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
Astellas Pharma Inc
AstraZeneca PLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
Janssen Pharmaceuticals Inc.
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
